WARNING: This product is for research use only, not for human or veterinary use.
MedKoo CAT#: 562318
CAS#: 1281870-42-5 (HCl)
Description: Rhosin hydrochloride is a Rho GTPase inhibitor. It acts by inhibiting binding of RhoA to guanine nucleotide exchange factors (GEFs) including LARG, DBL, LBC, p115 RhoGEF and PDZ RhoGEF.
MedKoo Cat#: 562318
Name: Rhosin hydrochloride
CAS#: 1281870-42-5 (HCl)
Chemical Formula: C20H19ClN6O
Exact Mass:
Molecular Weight: 394.86
Elemental Analysis: C, 60.84; H, 4.85; Cl, 8.98; N, 21.28; O, 4.05
Related CAS #: 1173671-63-0 (free base) 1281870-42-5 (HCl)
Synonym: Rhosin hydrochloride; Rhosin HCl; G04;
IUPAC/Chemical Name: D-Tryptophan (2E)-2-(6-quinoxalinylmethylene)hydrazide hydrochloride
InChi Key: SFRGBDFQSLZYLF-GRYLRVQNSA-N
InChi Code: InChI=1S/C20H18N6O.ClH/c21-16(10-14-12-24-17-4-2-1-3-15(14)17)20(27)26-25-11-13-5-6-18-19(9-13)23-8-7-22-18;/h1-9,11-12,16,24H,10,21H2,(H,26,27);1H/b25-11+;/t16-;/m1./s1
SMILES Code: N[C@H](CC1=CNC2=C1C=CC=C2)C(N/N=C/C3=CC=C4N=CC=NC4=C3)=O.[H]Cl
Appearance: Solid powder
Purity: >98% (or refer to the Certificate of Analysis)
Shipping Condition: Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.
Storage Condition: Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).
Solubility: Soluble in DMSO
Shelf Life: >2 years if stored properly
Drug Formulation: This drug may be formulated in DMSO
Stock Solution Storage: 0 - 4 C for short term (days to weeks), or -20 C for long term (months).
HS Tariff Code: 2934.99.9001
The following data is based on the product molecular weight 394.86 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.
| Concentration / Solvent Volume / Mass | 1 mg | 5 mg | 10 mg |
|---|---|---|---|
| 1 mM | 1.15 mL | 5.76 mL | 11.51 mL |
| 5 mM | 0.23 mL | 1.15 mL | 2.3 mL |
| 10 mM | 0.12 mL | 0.58 mL | 1.15 mL |
| 50 mM | 0.02 mL | 0.12 mL | 0.23 mL |
1: Lin HX, Yang MS, Tian C, Han CR, Song J, Duan JF, Jiang JX. Design of diversified self-assembly systems based on a natural rosin-based tertiary amine for doxorubicin delivery and excellent emulsification. Colloids Surf B Biointerfaces. 2018 Jan 31;165:191-198. doi: 10.1016/j.colsurfb.2018.01.049. [Epub ahead of print] PubMed PMID: 29482130.
2: Bajwa A, Rosin DL, Chroscicki P, Lee S, Dondeti K, Ye H, Kinsey GR, Stevens BK, Jobin K, Kenwood BM, Hoehn KL, Lynch KR, Okusa MD. Sphingosine 1-phosphate receptor-1 enhances mitochondrial function and reduces cisplatin-induced tubule injury. J Am Soc Nephrol. 2015 Apr;26(4):908-25. doi: 10.1681/ASN.2013121351. Epub 2014 Aug 21. PubMed PMID: 25145931; PubMed Central PMCID: PMC4378101.
3: Bajwa A, Jo SK, Ye H, Huang L, Dondeti KR, Rosin DL, Haase VH, Macdonald TL, Lynch KR, Okusa MD. Activation of sphingosine-1-phosphate 1 receptor in the proximal tubule protects against ischemia-reperfusion injury. J Am Soc Nephrol. 2010 Jun;21(6):955-65. doi: 10.1681/ASN.2009060662. Epub 2010 Mar 25. PubMed PMID: 20338995; PubMed Central PMCID: PMC2900956.
4: Lopes CT, Rosin FC, Cordeiro JA, Bueno V. Cell phenotype evaluation at various sites after skin transplantation and FTY720 plus sirolimus therapy. Transplant Proc. 2010 Mar;42(2):573-7. doi: 10.1016/j.transproceed.2010.01.027. PubMed PMID: 20304195.
5: Nande VS, Barabde UV, Morkhade DM, Joshi SB, Patil AT. Investigation of PEGylated derivatives of rosin as sustained release film formers. AAPS PharmSciTech. 2008;9(1):105-11. doi: 10.1208/s12249-007-9025-5. Epub 2008 Jan 16. PubMed PMID: 18446469; PubMed Central PMCID: PMC2976905.
6: Morkhade DM, Nande VS, Barabde UV, Patil AT, Joshi SB. PEGylated rosin derivatives: novel microencapsulating materials for sustained drug delivery. AAPS PharmSciTech. 2007 Jun 22;8(2):Article 47. PubMed PMID: 17622122; PubMed Central PMCID: PMC2750362.
7: Fulzele SV, Satturwar PM, Dorle AK. Novel biopolymers as implant matrix for the delivery of ciprofloxacin: biocompatibility, degradation, and in vitro antibiotic release. J Pharm Sci. 2007 Jan;96(1):132-44. PubMed PMID: 16960824.
8: Welk A, Splieth CH, Schmidt-Martens G, Schwahn Ch, Kocher T, Kramer A, Rosin M. The effect of a polyhexamethylene biguanide mouthrinse compared with a triclosan rinse and a chlorhexidine rinse on bacterial counts and 4-day plaque re-growth. J Clin Periodontol. 2005 May;32(5):499-505. PubMed PMID: 15842266.
9: Rosin M, Welk A, Kocher T, Majic-Todt A, Kramer A, Pitten FA. The effect of a polyhexamethylene biguanide mouthrinse compared to an essential oil rinse and a chlorhexidine rinse on bacterial counts and 4-day plaque regrowth. J Clin Periodontol. 2002 May;29(5):392-9. PubMed PMID: 12060421.
10: Rosin M, Benjamin P, Rogers P, Gibson M, Van Leuven F, Johnson NW, Curtis M. Elevated conversion of alpha-2-macroglobulin to the complexed form in gingival crevicular fluid from adult periodontitis patients. J Periodontal Res. 1995 Nov;30(6):436-44. PubMed PMID: 8544108.
11: Sevgi F, Ozyazici M, Güneri T. Sustained-release dosage form of phenylpropanolamine hydrochloride (3). Application of factorial design. J Microencapsul. 1994 Jul-Aug;11(4):439-44. PubMed PMID: 7931943.
12: Seldin DW, Rosin JM, rector FC Jr. Evidence against bicarbonate reabsorption in the ascending limb, particularly as disclosed by free-water clearance studies. Yale J Biol Med. 1975 Sep;48(4):337-47. PubMed PMID: 1202762; PubMed Central PMCID: PMC2595177.
